文献速递头颈外科

采用NI-RADS评估根治性放(化)疗后头颈部鳞状细胞癌FDG-PET/CECT反应评估的诊断性能

Diagnostic Performance of Response Assessment FDG-PET/CECT in HNSCC Treated With Definitive Radio(chemo)therapy Using NI-RADS.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-03-01

回顾性分析190例接受根治性放(化)疗的头颈部鳞状细胞癌患者的治疗后FDG-PET/CECT,按NI-RADS分类评估原发灶、颈部及两者联合的诊断性能。原发灶敏感度73.5%、特异度81.4%、总准确率80.0%;颈部分别为72.7%、87.5%、85.8%;联合分别为84.4%、69.7%、73.2%。中位随访40个月,NI-RADS 1类2年局部区域控制率94.2%,显著高于2类69.4%和3类20.4%。

要点

  • NI-RADS用于根治性放(化)疗后HNSCC反应评估,原发灶总准确率80.0%,颈部85.8%。
  • NI-RADS 1类2年局部区域控制率94.2%,显著高于2类69.4%和3类20.4%(分层log-rank p<.0001)。
  • FDG-PET/CECT结合NI-RADS模板在该人群中具有良好诊断性能和预后价值。

核心结论

  • 采用NI-RADS模板的FDG-PET/CECT在根治性放(化)疗后的HNSCC中具有良好诊断性能和预后价值。

研究设计与样本

  • 回顾性分析来自前瞻性维护数据集,纳入190例新诊断、活检证实、非转移性、接受根治性放(化)疗的成人HNSCC患者。
  • 治疗后FDG-PET/CECT扫描回顾性分配NI-RADS分类(1-3类),分别针对原发灶、颈部及两者联合。
  • 事件定义为2年内发生的局部区域复发;计算敏感度、特异度、阳性预测值(PPV)、阴性预测值(NPV)和总准确率;采用Kaplan-Meier法计算按NI-RADS分类分层的局部区域控制率,并用log-rank检验比较。
  • 研究地点为低中等收入国家的一家三级综合癌症中心。

主要发现

  • 原发灶NI-RADS模板的敏感度73.5%、特异度81.4%、PPV 46.3%、NPV 93.4%、总准确率80.0%。
  • 颈部相应指标分别为敏感度72.7%、特异度87.5%、PPV 43.2%、NPV 96.1%、总准确率85.8%。
  • 原发灶与颈部联合的相应诊断准确率指标分别为敏感度84.4%、特异度69.7%、PPV 46.3%、NPV 93.5%、总准确率73.2%。
  • 中位随访40个月,NI-RADS 1类的2年局部区域控制率为94.2%,显著高于2类的69.4%和3类的20.4%(分层log-rank p<.0001)。

关键数值与推荐

  • 原发灶:敏感度73.5%、特异度81.4%、PPV 46.3%、NPV 93.4%、总准确率80.0%。
  • 颈部:敏感度72.7%、特异度87.5%、PPV 43.2%、NPV 96.1%、总准确率85.8%。
  • 原发灶与颈部联合:敏感度84.4%、特异度69.7%、PPV 46.3%、NPV 93.5%、总准确率73.2%。
  • 2年局部区域控制率:NI-RADS 1类94.2% vs 2类69.4% vs 3类20.4%(分层log-rank p<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the diagnostic performance of response assessment 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography (FDG-PET/CECT) following definitive radio(chemo)therapy in head and neck squamous cell carcinoma (HNSCC) using Neck Imaging Reporting and Data System (NI-RADS). STUDY DESIGN: A retrospective analysis from a prospectively maintained dataset. SETTING: Tertiary-care comprehensive cancer center in a low-middle-income country. METHODS: Adults with newly diagnosed, biopsy-proven, nonmetastatic HNSCC treated with definitive radio(chemo)therapy were included. Posttreatment response assessment FDG-PET/CECT scans were retrospectively assigned NI-RADS categories (1-3) for the primary site, neck, and both sites combined. Locoregional recurrence occurring within 2-years was defined as the event of interest. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy were calculated. Locoregional control stratified by NI-RADS categories was computed with the Kaplan-Meier method and compared using the log-rank test. RESULTS: Posttreatment FDG-PET/CECT scans were available in 190 patients constituting the present study cohort. Sensitivity, specificity, PPV, NPV, and overall accuracy of the NI-RADS template for the primary site was 73.5%, 81.4%, 46.3%, 93.4%, and 80.0%, respectively. Similar metrics for the neck were 72.7%, 87.5%, 43.2%, 96.1%, and 85.8%, respectively. Combining primary site and neck, the corresponding metrics of diagnostic accuracy were 84.4%, 69.7%, 46.3%, 93.5%, and 73.2%, respectively. At a median follow-up of 40 months, Kaplan-Meier estimates of 2-year locoregional control were significantly higher for NI-RADS category 1 (94.2%) compared to NI-RADS category 2 (69.4%) and category 3 (20.4%), respectively (stratified log-rank p < .0001). CONCLUSION: FDG-PET/CECT using the NI-RADS template is associated with good diagnostic performance and prognostic utility in HNSCC treated with definitive radio(chemo)therapy.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Paul S, Gupta T, Purandare N, et al. Diagnostic Performance of Response Assessment FDG-PET/CECT in HNSCC Treated With Definitive Radio(chemo)therapy Using NI-RADS. Otolaryngol Head Neck Surg. 2023. PMID: 36856038. doi:10.1002/ohn.305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。